A T cell redirecting bispecific protein consisting of an affinity enhanced T cell receptor fused to an anti-CD3 molecule that engages gp100 presented by major histocompatibility complex class I HLA-A 02:01 on tumor cells.
A bispecific molecule that binds to the GP 100 protein on one end and to CD 3T cells on the other end.
The GP 100 protein is highly expressed on melanoma cells so binding to both this protein and T cells brings immune cells directly to the tumor.
Patients must be positive for the human leukocyte antigen (HLA) A *02:01 serotype to be eligible for treatment.
For the treatment of metastatic uveal melanoma in patients positive for HLA-A02:01 with metastatic or unresectable uveal melanoma.
It demonstrated superior overall survival and progression free survival compared with it Pembrolizumab, Ipilimumab, or dacarbazine.
Objective response rate was only 9% but the disease control rate was 46%, suggesting clinical benefit without substantial to reduction on imaging studies.
Associated with cytokine release syndrome, rash and requires in patient monitoring for the first three doses.
In a three-year efficacy and safety trial patients were treated withTebentafusp versus Pembrolizumab, ipilimumab or dacarbazine control.
At three years, 27% in theTebentafusp group survived and 18% in the control group.
The overall survival was statistically significantly longer in the tebentafusp group, than in control group at 21.6 versus 16.9 months.
Tebentafusp toxicity included rash and 83%, pyrexia, 76%, pus in 70%, and hypotension and 38%: only 2% of the treatment group discontinued therapy.
Despite a survival benefit, there was an absence of visible tumor response.